HIT Consultant May 16, 2024
What You Should Know:
– Phenomix Sciences (Phenomix), a precision medicine biotechnology company that brings data intelligence to the treatment of obesity, has secured $5.5 million in Series A funding from new investors, DexCom, Inc. and Labcorp, and existing investors, including Health2047.
– The company has also been awarded a $2.3 million Phase II Small Business Innovation Research (SBIR) Grant through the National Institutes of Health (NIH).
Driving Precision Medicine in Obesity Treatment: Phenomix’s MyPhenome™ Test and Strategic Growth Initiatives
This infusion of capital will expedite the commercialization and uptake of the MyPhenome™ test within the obesity specialist market and broader industry. Equipping physicians with vital tools, the MyPhenome test facilitates the development of effective treatment strategies encompassing lifestyle...
Today's Sponsors
Today's Sponsor